Salt Forms of a Kinase Inhibitor
US-2023052703-A1 · Feb 16, 2023 · US
Crystalline forms and salt forms of a kinase inhibitor
US12017995B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12017995-B2 |
| Application number | US-201917312658-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 12, 2019 |
| Priority date | Dec 13, 2018 |
| Publication date | Jun 25, 2024 |
| Grant date | Jun 25, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
First claim
Opening claim text (preview).
The invention claimed is: 1. A crystalline hemifumarate salt of Compound 1 having the structure 2. A pharmaceutical composition comprising the crystalline hemifumarate salt of Compound 1 according to claim 1 and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Crystalline forms, e.g. polymorphs · CPC title
Quinolines; Isoquinolines · CPC title
Antineoplastic agents · CPC title
- C07D215/48Primary
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12017995B2 cover?
- The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome med…
- Who is the assignee on this patent?
- Exelixis Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D215/48. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).